Background: The HSD11B2 gene, encoding the kidney isoenzyme 11␤-hydroxysteroid dehydrogenase, is a candidate for essential hypertension. We previously showed that the frequency of shorter alleles of a CA repeat polymorphism in the first intron of 11␤-HSD2 gene was significantly higher among salt-sensitive than salt-resistant individuals with hypertension. The aim of the study was to analyze the HSD11B2 gene to assess whether some of its variants might be involved in hypertension.
Mutations in the HSD11B2 gene cause the syndrome of apparent mineralocorticoid excess (AME), characterized by severe hypertension, hypokalemia and low plasma renin activity. 7, 8 In this condition, absence of 11␤-HSD2 prevents conversion of cortisol into cortisone, resulting in a rise in intracellular cortisol levels, overstimulation of the mineralocorticoid receptor (MR), and cortisol-induced mineralocorticoid excess. 9, 10 The AME syndrome arises because of mutations in HSD11B2, inherited as an autosomal recessive trait. Both homozygous 11 and compound heterozygous mutations have been reported. 12 Principally in exons 3 to 5 the gene mutations been detected which significantly impair 11␤-HSD2 enzymatic activity.
A second variant of AME, the so-called AME type II, 13 is characterized by a milder phenotype with onset in late adolescence or early adulthood and by a less deranged cortisol metabolism compared with the classical disease. Nevertheless these patients also have mutations within the HSD11B2 gene, and a classification of this syndrome into distinct variants is inappropriate. The AME syndrome should be considered a continuum disorder in which defects of HSD11B2 gene encoding mutant cDNA result in varying degrees of enzymatic impairment. Deficient cortisol inactivation and increased excretion of urinary cortisol metabolites have been reported in patients with essential hypertension. 14 The detection of heterozygous 15 and homozygous 16 mutations associated with mineralocorticoid hypertension, the presence of short alleles of CA-repeat microsatellites associated with saltsensitive hypertension, 17 and the demonstration of microsatellite A7/A7 in salt-sensitive normotensive subjects 18 suggest that the 11␤-HSD2 isoform may have an important role in essential hypertension and in salt sensitivity. A recent study of the renin-angiotensin-aldosterone system gene polymorphisms showed that the insertion-deletion polymorphism ACE I/D and HSD11B2 G534A polymorphism were significantly associated with the blood pressure (BP) response to high salt in patients with hypertension. 19 These findings suggest that the two polymorphisms may be used as genetic markers for salt sensitivity.
The aim of this study was to analyze the coding sequence of the HSD11B2 gene in a group of hypertensive patients to assess whether its more common variants might be implicated in hypertension. We also conducted a casecontrol study in hypertensive patients and normotensive control subjects to understand whether the two polymorphisms of the HSD11B2 gene identified in the course of the investigation have a role in essential hypertension and in salt sensitivity.
Methods

Study Subjects
We studied 455 unrelated subjects of white ethnicity, 292 patients with essential hypertension (134 men and 158 women) and 163 normotensive control subjects (84 men and 79 women). The hypertensive group includes 90 patients of Italian Salt-Sensitivity Study group (SISS) recruited by northern, central, and southern Italy excluding the Islands (Sardinia and Sicily) with the following features, as previously described. 20 All of them had mild uncomplicated essential hypertension, body mass index (BMI) Ͼ21 or Ͻ28 kg/m 2 , and age Ͼ25 or Ͻ65 years. After complete clinical, biochemical and radiologic examination, patients with secondary hypertension, renal failure, coronary heart disease, cerebrovascular disease, diabetes mellitus, or concurrent serious illness, as well as women taking hormonal therapy, were excluded. A total of 202 patients with essential hypertension were consecutively recruited, using the same criteria, from the Division of Endocrinology, Umberto I Hospital (Ancona, Italy). Hypertensive subjects were either receiving treatment for high BP or, if untreated, had a diastolic BP (DBP) of Ն95 mm Hg and systolic BP (SBP) Յ160 mm Hg on at least two consecutive occasions.
The normotensive group included selected subjects recruited in part from various Italian centers (n ϭ 70, from northern, central, and southern Italy excluding Sardinia and Sicily) and in large part (n ϭ 93) from the Division of Endocrinology and Centro Trasfusionale, Umberto I Hospital (Ancona, Italy). The control subjects were selected on the basis of the following criteria: 1) DBP and SBP values of Յ80 mm Hg and Յ140 mm Hg, respectively; 2) age Ն55 years to reduce the possibility that they would eventually develop hypertension; 3) no clinical evidence of disease that might lower BP; 4) negative family history for hypertension and cardiovascular disease; and 5) BMI Ͻ27 to exclude the possible interaction of the weight on BP.
Before biochemical and hormonal analysis and salt sensitivity test were performed, all subjects (hypertensive and normotensive) had received in the previous 3 days a normal sodium diet (150 nmol/day). The study was approved by the Ethical Committee of our Hospital and was performed in accordance with the guidelines of the Declaration of Helsinki. All patients gave their informed consent.
Salt-Sensitivity Test
The salt-sensitivity test, modified from the protocol of Grim et al, 21 was administered to 90 patients of SISS and other 68 patients recruited from hypertensive subjects. Patients were taken off antihypertensive medication regimens for 14 days and treated according to an acute saltloading and salt-depletion protocol after they had been given a normal sodium diet (150 nmol/day) for 3 days. In each patient normal saline (0.9% NaCl 2 L) was infused over 4 h (salt loading) and the next day three 37.5-mg doses of furosemide were given by mouth at 8 AM, 4 PM, and 8 PM (salt depletion), as previously described. 20 If the difference between the mean arterial pressures at the end of the salt-loading and salt-depletion periods was Ͼ10 mm Hg, a patient was classified as "salt sensitive"; otherwise that patient was considered "salt resistant."
Hormonal and Clinical Parameters
Clinical, biochemical, and hormonal parameters were evaluated in all patients. Plasma renin activity (PRA; ng/mL/h) was determined as angiotensin I using radioimmunoassay coated tubes (RIA CT assay-RADIM, Rome, Italy); the method sensitivity is 0.15 ng/mL, intra-assay concentration variability (CV) 4.5%, and inter-assay CV 7.7%. Plasma aldosterone was determined using a Radioactive iodine uptake (RAIU) (MAIA BIOCHEM IMMUNOSYSTEM, Bologna, Italy); its sensitivity is 6.0 pg/mL, intra-assay CV 5.4%, and inter-assay CV 6.3%.
Steroid Analysis
In the patients with the SISS protocol and in 20 normotensive control subjects, a 24-h urine collection was obtained and was analyzed for urinary free cortisol and urinary free cortisone levels by gas chromatography and mass spectrometry using a stable isotope-labeled internal standard. 22 The steroid analysis was performed after discontinuation of any antihypertensive treatment for at least 2 weeks. The precursor/product ratio, urinary free cortisol/urinary free cortisone ratio (UFF/UFE), is inversely related to activity in vivo and provides a robust measure of the activity of this enzyme.
Extraction of Genomic DNA and Polymerase Chain Reaction Analysis
The genomic DNA of all subjects was extracted from peripheral blood cells using isopropanol and its concentration was determined by measuring adsorption at 260 nm.
The oligonucleotides for polymerase chain reaction (PCR) were selected to generate products not exceeding 350 base pairs (bp) using the OLIGO 5.0 primer analysis software based on GenBank human genomic sequences (National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD). Primers were derived from the intronic sequences flanking exons 2, 3, 4 and from the exonic sequences for exon 5 ( Table 1 ). The PCR analysis was performed in a 50 L reaction buffer using 200-ng template DNA, 0.5 mmol/L of each primer (M-Medical Genenco Srl, Florence, Italy), 0.2 nmol/L of each dNTP (Fynnzymes CELBIO Srl Pero, Milan, Italy), and 1.5 U of Taq polymerase (Fynnzymes CELBIO Srl Pero, Milan, Italy) in 10 X reaction buffer (10 mmol/L TRIS-HCl, 1.5 mmol/L MgCl 2 , 50 mmol/L KCl, and 0.1% Triton x100). Amplifications were carried out in a Gene Amp 9700 thermal cycler (Applied Biosystems, Norwalk, CT) and reactions were performed as follows: initial denaturation at 94°C for 5 min, 35 cycles of 94°C for 30 sec, annealing temperature for 30 sec (Table 1 ) and 72°C for 30 sec, and final extension at 72°C for 7 min. The PCR products were visualized using 2% agarose gel and ethidium bromide.
Single-Strand Conformation Polymorphism Analysis
We used the single-strand conformation polymorphism (SSCP) technique to detect point mutations of the HSD11B2 gene. After PCR amplification, exons 2, 3, 4, and 5 of the HSD11B2 gene of the 158 subjects characterized for salt sensitivity (90 patients) were analyzed by SSCP on 0.5 ϫ MDE gels (FMC BIOSPA, Milano, Italy) prepared in 0.5 ϫ 90 mmol/L Tris-borate, pH 7.8, at 25 W constant power for appropriate times for each exon. The gels were stained using Gel Star Nucleic Acid Gel Stain (FMC BIOSPA, Milano, Italy). All samples were then diluted twofold in a solution containing 95% formamide, 20% ethylenediamenetetraacetate, pH 8.0, 5% sodium dodecyl sulfate, 0.05% xylene cyanol, and 0.05% bromophenol blue and denatured at 95°C for 5 min. The PCR fragments measuring Ͼ250 bp were digested by adding 5 U of a specific restriction enzyme to obtain fragments of approximately150 bp and to maximize the probability of detecting SSCP variants. The SSCP variants were identified by comparing the migration of corresponding PCR fragments generated from a normal sample run in the same gel.
In the other hypertensive patients (n ϭ 134) and in all control subjects (n ϭ 163), only exon 2 was subjected to SSCP analysis, whereas the SNP in exon 3 was identified with restriction analysis. The SSCP was performed twice in all samples.
Direct Sequencing and Restriction Analysis
Samples presenting mobility shifts at SSCP analysis for exon 2 were reamplified for direct sequencing of forward and reverse sequences. The PCR products were purified (JET quick PCR Purification Spin GENOMED, Lohne, Germany) and the DNA was sequenced using an automated DNA sequencer (ABI Prism 310, Applied Biosystems, Norwalk, CT) using dye-labeled dideoxynucleotides (Big Dye Terminator Cycle Sequencing Ready Reaction Kit, Applied Biosystems). Purification of sequence products from excess dye terminators was performed by spin column separation (Centri-Sep columns, Applied Biosystems).
Samples presenting mobility shifts at SSCP analysis for exon 3 were digested using the restriction enzyme AluI (AG2CT), which recognizes a new cutting site formed by the substitution of G with A in the same AACT sequence. Restriction analysis was performed using 5 U Alu I (New England Biolabs, Beverly, MA) in a specific buffer at 37°C overnight, and was controlled using 3% agarose gel.
Statistical Analysis
We used the Statview software for Windows (SAS Institute, Cary, NC) to carry out the statistical analysis. Genotype and allele frequencies were determined and analyzed by the 2 test. With an ␣-error of 0.05% the sample size provided a power of 76% to detect the difference in genotype frequency for ex2 polymorphism between hypertensive subjects and normotensive subjects. The sample size provided a power of 86%, with an ␣-error of 0.05%, to detect the difference in ex2/ex3 polymorphisms association between hypertensive patients and control subjects. A 2 goodness of fit test was used to check HardyWeinberg equilibrium.
The statistical analysis between two or more groups was performed using the analysis of variance. Bonferroni's correction was then applied to reduce the probability of differences arising by chance. Data are reported as mean Ϯ SE. A P value Ͻ .05 was considered statistically significant.
Results
Clinical and Hormonal Characteristics
The clinical and hormonal characteristics of our hypertensive subjects and control subjects are reported in Table 2 .
The control subjects enrolled in the study were older than the hypertensive subjects (57 Ϯ 1.1 v 47 Ϯ 0.9 years) to reduce the possibility that they would eventually develop hypertension. The normotensive subjects had no familiarity for hypertension or cardiovascular diseases.
There were significant differences between hypertensive patients and control subjects in regard to SBP, DBP, or BMI. The BMI was significantly different between the two groups but hypertensive subjects were overweight and not obese so to exclude weight influence on BP. The UFF/UFE ratio was significantly higher in hypertensive patients than in control subjects (P Ͻ .01).
Single-Strand Conformation Polymorphism Analysis and Direct Sequencing
The SSCP conditions for exons 2, 3, 4 and 5 of the HSD11B2 gene were optimized to study the 158 patients characterized for salt sensitivity and resistance. In these subjects, genetic variations were found in exon 2 (ex2) and exon 3 (ex3): Thr156/Thr (C468A) in ex2 and Glu178/Glu (G534A) in ex3 (Fig. 1) . Neither polymorphism changed Aldo ϭ aldosterone; BMI ϭ body mass index; CVD ϭ cardiovascular disease; DBP ϭ diastolic blood pressure; PRA ϭ plasma renin activity; SBP ϭ systolic blood pressure; UFF/UFE ϭ urinary free cortisol /urinary free cortisone ratio.
the coding sequence. In one hypertensive patient we found a different substitution, Thr112/Thr (C336T) in ex3, which also did not change the coding sequence.
Genotyping: Case Control Study
In the course of the above investigation of the coding sequence of the HSD11B2 gene, we identified in ex2 a new polymorphism, Thr 156/Thr (C468A), which did not change the coding sequence. The homozygous CC genotype (91%) was more frequent than the heterozygous CA genotype (9%) in the hypertensive patients as well as in the normotensive subjects (97% v 3%). The homozygous AA genotype of C468A polymorphism was not found (Table 3) . A second polymorphism, Glu 178/Glu (G534A), was found in ex3. In both groups of subjects, homozygous GG genotype was more frequent than the heterozygous GA genotype (91% v 9% in hypertensive patients and 93% v 7% in normotensive subjects). The homozygous AA genotype of G534A polymorphism was not found (Table 3 ). There was a significant difference in genotype frequency for the C468A ex2 polymorphism between cases and control subjects (P Ͻ .05) ( Table 3 ).
The two polymorphisms were in Hardy-Weinberg equilibrium. Association analysis of the two polymorphisms was conducted using the 2 test in the two groups of subjects. The association of CC alleles in ex2 and GG alleles in ex3 was found in 91% of hypertensive subjects and 92% of normotensive subjects (Table 4 ). The association of the two polymorphic alleles, CA in ex2 and GA in ex3, was found in 9% of hypertensive subjects and 2.4% of normotensive subjects (P Ͻ .0001) ( Table 4 ). The other combinations are not present. All hypertensive patients with the CA polymorphism in ex2 also showed the GA polymorphism in ex3, and were heterozygous for the two polymorphisms.
Phenotyping
A correlation between UFF/UFE ratio and genotype ex2 CA/ex3 GA or ex2 CC/ex3 GG was sought in the hypertensive patients. A significantly higher UFF/UFE ratio was associated with the former genotype (P Ͻ .01). There was no correlation between the other clinical and hormonal parameters and the polymorphisms in hypertensive subjects (Table 5) .
We found no correlation between the ex2/ex3 polymorphisms and salt resistance or sensitivity in our hypertensive patients. In the subgroup of hypertensive subjects characterized by salt sensitivity or resistance, the UFF/ UFE ratio and 24 h sodium excretion were significantly higher in the salt-sensitive patients (P Ͻ .005 and P Ͻ .05 respectively), and plasma aldosterone in the salt-resistant ones (P Ͻ .05). There was no correlation between the other clinical and hormonal parameters and the polymorphisms in the salt-sensitive or resistant hypertensive subjects (Table 6 ).
Discussion
The present study was carried out to investigate whether genetic alterations in the coding sequence of the HSD11B2 gene encoding the 11␤-HSD2 enzyme could be involved in essential hypertension, particularly in salt-sensitive hypertension, as an association has been demonstrated between the short alleles of a microsatellite located in intron 1 of HSD11B2 gene and salt sensitivity in hypertension 17 and between an allele of microsatellite D165496 and hypertension in a population of African American patients with hypertension and renal insufficiency. 23 Moreover an increased UFF/ UFE ratio, an index of 11␤-HSD2 activity, has also been noted in salt-sensitive hypertensive patients. 22, 24 The increased excretion of urinary cortisol metabolites in some patients with essential hypertension also argues for the involvement of 11␤-HSD2 in hypertension. In this study, hypertensive subjects had a significantly higher UFF/UFE ratio than normotensive subjects, suggesting the impaired 11␤-HSD2 activity.
Analysis of the HSD11B2 coding region (exons 2, 3, 4, and 5) demonstrated two polymorphisms: Thr156/Thr (C468A) in ex2 and Glu178/Glu (G534A), as previously described 25 in ex3. The greater frequency of the former polymorphism in the hypertensive group compared with the normotensive group suggests that this trait could have a functional role in reducing the activity of the 11␤-HSD2 enzyme, in line with the observation that intragenic polymorphisms frequently affect gene function. 26 Because individual exons comprise multiple positive and negative cis elements that affect splicing, some exonic SNP, by modifying the consensus sequences of the exon splicing enhancer (ESE) proteins, may influence splicing efficiency or accuracy, and therefore gene expression levels, resulting in variable severity of clinical phenotypes. 27 It will now be important to verify the role of these two polymorphisms by constructing the minigene required to evaluate pre-mRNA splicing.
Our hypertensive patients consistently exhibited an association of the ex2 and ex3 polymorphisms and, interestingly, a UFF/UFE ratio that much exceeded the normal range and was greater than in both the normotensive and other hypertensive subjects. 22 This association was significantly more frequent in the hypertensive than the normotensive subjects. Indeed, although in the latter subjects it was more common to find one or the other polymorphism, in the hypertensive patients it was both or neither. Although we found no difference in terms of ex3 polymorphism frequency in hypertensive subjects and in normotensive subjects, Zaehner et al 28 reported a higher frequency of this SNP in hypertensive subjects compared with healthy control subjects. Such difference could result from the genetic heterogeneity and the a smaller number of subjects studied in the above-mentioned work compared with our study. Indeed our findings are in line with data from Lovati et al, 18 suggesting that it is likely that ex3 polymorphism does not affect the enzyme on a functional level, even though in our hypertensive subjects it was consistently associated with the ex2 polymorphism. This suggests recombinational events favoring the simultaneous presence of the two polymorphisms in these subjects, as well as the possibility of their association and segregation with some other genetic modifications upstream from exon 2.
It may thus be hypothesized that a decreased expression, rather than an altered sequence, of the 11␤-HSD2 enzyme pertains in hypertension, and in particular in a subgroup of hypertensive subjects who exhibit a com- bination of both polymorphisms. The increased UFF/ UFE ratio, which appears to be a sensitive marker of impaired renal 11␤-HSD2 enzymatic activity, found in our hypertensive subjects might be related to alterations and/or polymorphisms in the promoter gene region affecting the expression of the HSD11B2 gene, as demonstrated for other genes. 29 It would therefore be interesting to learn more about the HSD11B2 promoter region of these patients, also in the light of the report by Nawrocki et al 30 and of the more recent paper by AlikaniKoopaei et al 31 showing the relevance of the CpG methylation status of the promoter region for 11␤-HSD2 expression and activity.
Our data also demonstrate that the UFF/UFE ratio was higher in salt-sensitive than salt-resistant hypertensive patients, reflecting reduced 11␤-HSD2 activity in the former. However, at variance with the results of the study of the intron 1 CA repeat microsatellite, 17 the association of the two polymorphisms correlates neither with salt sensitivity nor with salt resistance. It is possible that the increased UFF/UFE ratio found in saltsensitive patients, and which correlates with intron 1 CA short alleles, is not related to the exon 2 and 3 HSD11B2 polymorphisms. This apparent divergence is to underlie that HSD11B2 is certainly involved in hypertension as demonstrated by the presence of the two above-mentioned polymorphisms in hypertensive patients, as well as that it is implicated in salt sensitivity but with a different genetic contribution with respect to the polymorphisms. Moreover, the sample of patients bearing the association and studied for salt sensitivity is certainly insufficient for data interpretation. The evaluation of UFF/UFE ratio with a more feasible technique (ie, a technique using high-performance liquid chromatography that has been developed in our laboratory, unpublished data) in a wider population characterized for salt-sensitivity, would be helpful for data interpretation.
The lack of an association between the two polymorphisms and the salt-sensitive phenotype is also in line with the study of Poch et al. 19 the hypothesis may thus be advanced that mutations in linkage with other genes could occur in salt sensitivity.
The correlation of the C468A polymorphism with hypertension could indicate the functional influence of this polymorphism on 11␤-HSD2 enzyme activity and on high BP development. Because a subgroup of our hypertensive patients exhibited a double polymorphism and an activity of the 11␤-HSD2 enzyme that was even lower than that observed in the other hypertensive patients, the double polymorphism might affect the HSD11B2 gene transcription, it might be a mere marker associated with alterations of the regulatory area of the gene itself, or be in linkage with other genes. Table 2 .
